drugset / Trial / NCT04706715
LAG3 PET Imaging in Advanced Solid Tumors
Phase 1/2
Active not recruiting
41 enrolled
University Medical Center Groningen
Regeneron Pharmaceuticals · collab
Non-randomizedSingle-groupOpen-labelOther
Summary
This is an investigator-initiated, single-center, open-label clinical trial designed to evaluate the safety and PK of the PET tracer 89Zr-DFO-REGN3767 in patients prior to and during treatment.
Timeline
- Start
- 2022-01-18
- Primary completion
- 2025-11
- Completion
- 2025-11
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | FIANLIMAB DFO ZR-89 | Monoclonal antibody | — | — |
| Background | Cemiplimab | Monoclonal antibody | 350 mg | — |